Patents by Inventor Michal Cardon-Yaakov

Michal Cardon-Yaakov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified kisspeptin peptides and uses thereof
    Patent number: 10072044
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Grant
    Filed: June 12, 2016
    Date of Patent: September 11, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Schwartz-Eisenbach, Matityahu Fridkin, Michal Cardon-Yaakov
  • MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
    Publication number: 20160280739
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: June 12, 2016
    Publication date: September 29, 2016
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Michal SCHWARTZ-EISENBACH, Matityahu FRIDKIN, Michal CARDON-YAAKOV
  • Modified kisspeptin peptides and uses thereof
    Patent number: 9382293
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 5, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
  • Modified Kisspeptin Peptides and Uses Thereof
    Publication number: 20150051151
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
  • GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
    Patent number: 8716228
    Abstract: Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: May 6, 2014
    Assignee: YEDA Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Gil M Lewitus, Michal Cardon-Yaakov, Noga Ron-Harel
  • GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES
    Publication number: 20120135935
    Abstract: Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed.
    Type: Application
    Filed: May 27, 2010
    Publication date: May 31, 2012
    Inventors: Michal Eisenbach-Schwartz, Gil M. Lewitus, Michal Cardon-Yaakov, Noga Ron-Harel